The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET
John Kanki, PhD, has joined Neuroendocrine Tumor Research Foundation (NETRF) as Director of Research. In this position, Dr. Kanki will oversee the strategic, scientific, and
Neuroendocrine cancer community faces loss. Carol Branaman, vice chair and former chair of NETRF, passes from neuroendocrine cancer.
Listen and Learn Being diagnosed with neuroendocrine cancer can make you feel like you are alone, like you’ve been blindsided with the unknown. The NET
Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research Symposium on May 2-3, 2019, in Cambridge, MA. More than
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Mark A. Lewis, MD, Director of Gastrointestinal Oncology, Intermountain Healthcare, Utah, has joined the Board of Directors for the Neuroendocrine Tumor Research Foundation. Dr. Lewis,
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with